View in EDS HTML Full Text PDF Full Text

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.

Saved in:
Bibliographic Details
Title: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
Authors: Tuberculosis Trials Consortium (CORPORATE AUTHOR), Benator, Debra (AUTHOR), Bhattacharya, Mondira (AUTHOR), Bozeman, Lorna (AUTHOR), Burman, William (AUTHOR), Cantazaro, Antonino (AUTHOR), Chaisson, Richard (AUTHOR), Gordin, Fred (AUTHOR), Horsburgh, C Robert (AUTHOR), Horton, James (AUTHOR), Khan, Awal (AUTHOR), Lahart, Christopher (AUTHOR), Metchock, Beverly (AUTHOR), Pachucki, Constance (AUTHOR), Stanton, Llewellyn (AUTHOR), Vernon, Andrew (AUTHOR), Villarino, M Elsa (AUTHOR), Wang, Yong Chen (AUTHOR), Weiner, Marc (AUTHOR), Weis, Stephen (AUTHOR)
Source: Lancet. 8/17/2002, Vol. 360 Issue 9332, p528-534. 7p.
Abstract: Background: Rifapentine has a long half-life in serum, which suggests a possible treatment once a week for tuberculosis. We aimed to compare rifapentine and isoniazid once a week with rifampicin and isoniazid twice a week.Methods: We did a randomised, multicentre, open-label trial in the USA and Canada of HIV-negative people with drug-susceptible pulmonary tuberculosis who had completed 2 months of a 6-month treatment regimen. We randomly allocated patients directly observed treatment with either 600 mg rifapentine plus 900 mg isoniazid once a week or 600 mg rifampicin plus 900 mg isoniazid twice a week. Primary outcome was failure/relapse. Analysis was by intention to treat.Findings: 1004 patients were enrolled (502 per treatment group). 928 successfully completed treatment, and 803 completed the 2-year 4-month study. Crude rates of failure/relapse were 46/502 (9.2%) in those on rifapentine once a week, and 28/502 (5.6%) in those given rifampicin twice a week (relative risk 1.64, 95% CI 1.04-2.58, p=0.04). By proportional hazards regression, five characteristics were independently associated with increased risk of failure/relapse: sputum culture positive at 2 months (hazard ratio 2.8, 95% CI 1.7-4.6); cavitation on chest radiography (3.0, 1.6-5.9); being underweight (3.0, 1.8-4.9); bilateral pulmonary involvement (1.8, 1.0-3.1); and being a non-Hispanic white person (1.8, 1.1-3.0). Adjustment for imbalances in 2-month culture and cavitation diminished the association of treatment group with outcome (1.34; 0.83-2.18; p=0.23). Of participants without cavitation, rates of failure/relapse were 6/210 (2.9%) in the once a week group and 6/241 (2.5%) in the twice a week group (relative risk 1.15; 95% CI 0.38-3.50; p=0.81). Rates of adverse events and death were similar in the two treatment groups.Interpretation: Rifapentine once a week is safe and effective for treatment of pulmonary tuberculosis in HIV-negative people without cavitation on chest radiography. Clinical, radiographic, and microbiological data help to identify patients with tuberculosis who are at increased risk of failure or relapse when treated with either regimen. [ABSTRACT FROM AUTHOR]
Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Psychology and Behavioral Sciences Collection
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: pbh
DbLabel: Psychology and Behavioral Sciences Collection
An: 106840265
AccessLevel: 6
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Tuberculosis+Trials+Consortium%22">Tuberculosis Trials Consortium</searchLink> (CORPORATE AUTHOR)<br /><searchLink fieldCode="AR" term="%22Benator%2C+Debra%22">Benator, Debra</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bhattacharya%2C+Mondira%22">Bhattacharya, Mondira</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Bozeman%2C+Lorna%22">Bozeman, Lorna</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Burman%2C+William%22">Burman, William</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Cantazaro%2C+Antonino%22">Cantazaro, Antonino</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Chaisson%2C+Richard%22">Chaisson, Richard</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Gordin%2C+Fred%22">Gordin, Fred</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Horsburgh%2C+C+Robert%22">Horsburgh, C Robert</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Horton%2C+James%22">Horton, James</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Khan%2C+Awal%22">Khan, Awal</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Lahart%2C+Christopher%22">Lahart, Christopher</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Metchock%2C+Beverly%22">Metchock, Beverly</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Pachucki%2C+Constance%22">Pachucki, Constance</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Stanton%2C+Llewellyn%22">Stanton, Llewellyn</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Vernon%2C+Andrew%22">Vernon, Andrew</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Villarino%2C+M+Elsa%22">Villarino, M Elsa</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wang%2C+Yong+Chen%22">Wang, Yong Chen</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weiner%2C+Marc%22">Weiner, Marc</searchLink> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Weis%2C+Stephen%22">Weis, Stephen</searchLink> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Lancet%22">Lancet</searchLink>. 8/17/2002, Vol. 360 Issue 9332, p528-534. 7p.
– Name: Abstract
  Label: Abstract
  Group: Ab
  Data: <bold>Background: </bold>Rifapentine has a long half-life in serum, which suggests a possible treatment once a week for tuberculosis. We aimed to compare rifapentine and isoniazid once a week with rifampicin and isoniazid twice a week.<bold>Methods: </bold>We did a randomised, multicentre, open-label trial in the USA and Canada of HIV-negative people with drug-susceptible pulmonary tuberculosis who had completed 2 months of a 6-month treatment regimen. We randomly allocated patients directly observed treatment with either 600 mg rifapentine plus 900 mg isoniazid once a week or 600 mg rifampicin plus 900 mg isoniazid twice a week. Primary outcome was failure/relapse. Analysis was by intention to treat.<bold>Findings: </bold>1004 patients were enrolled (502 per treatment group). 928 successfully completed treatment, and 803 completed the 2-year 4-month study. Crude rates of failure/relapse were 46/502 (9.2%) in those on rifapentine once a week, and 28/502 (5.6%) in those given rifampicin twice a week (relative risk 1.64, 95% CI 1.04-2.58, p=0.04). By proportional hazards regression, five characteristics were independently associated with increased risk of failure/relapse: sputum culture positive at 2 months (hazard ratio 2.8, 95% CI 1.7-4.6); cavitation on chest radiography (3.0, 1.6-5.9); being underweight (3.0, 1.8-4.9); bilateral pulmonary involvement (1.8, 1.0-3.1); and being a non-Hispanic white person (1.8, 1.1-3.0). Adjustment for imbalances in 2-month culture and cavitation diminished the association of treatment group with outcome (1.34; 0.83-2.18; p=0.23). Of participants without cavitation, rates of failure/relapse were 6/210 (2.9%) in the once a week group and 6/241 (2.5%) in the twice a week group (relative risk 1.15; 95% CI 0.38-3.50; p=0.81). Rates of adverse events and death were similar in the two treatment groups.<bold>Interpretation: </bold>Rifapentine once a week is safe and effective for treatment of pulmonary tuberculosis in HIV-negative people without cavitation on chest radiography. Clinical, radiographic, and microbiological data help to identify patients with tuberculosis who are at increased risk of failure or relapse when treated with either regimen. [ABSTRACT FROM AUTHOR]
– Name: AbstractSuppliedCopyright
  Label:
  Group: Ab
  Data: <i>Copyright of Lancet is the property of Lancet and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.)
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=pbh&AN=106840265
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/s0140-6736(02)09742-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 7
        StartPage: 528
    Titles:
      – TitleFull: Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Tuberculosis Trials Consortium
      – PersonEntity:
          Name:
            NameFull: Benator, Debra
      – PersonEntity:
          Name:
            NameFull: Bhattacharya, Mondira
      – PersonEntity:
          Name:
            NameFull: Bozeman, Lorna
      – PersonEntity:
          Name:
            NameFull: Burman, William
      – PersonEntity:
          Name:
            NameFull: Cantazaro, Antonino
      – PersonEntity:
          Name:
            NameFull: Chaisson, Richard
      – PersonEntity:
          Name:
            NameFull: Gordin, Fred
      – PersonEntity:
          Name:
            NameFull: Horsburgh, C Robert
      – PersonEntity:
          Name:
            NameFull: Horton, James
      – PersonEntity:
          Name:
            NameFull: Khan, Awal
      – PersonEntity:
          Name:
            NameFull: Lahart, Christopher
      – PersonEntity:
          Name:
            NameFull: Metchock, Beverly
      – PersonEntity:
          Name:
            NameFull: Pachucki, Constance
      – PersonEntity:
          Name:
            NameFull: Stanton, Llewellyn
      – PersonEntity:
          Name:
            NameFull: Vernon, Andrew
      – PersonEntity:
          Name:
            NameFull: Villarino, M Elsa
      – PersonEntity:
          Name:
            NameFull: Wang, Yong Chen
      – PersonEntity:
          Name:
            NameFull: Weiner, Marc
      – PersonEntity:
          Name:
            NameFull: Weis, Stephen
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 08
              Text: 8/17/2002
              Type: published
              Y: 2002
          Identifiers:
            – Type: issn-print
              Value: 01406736
          Numbering:
            – Type: volume
              Value: 360
            – Type: issue
              Value: 9332
          Titles:
            – TitleFull: Lancet
              Type: main
ResultId 1